The definition and preoperative prediction of clinically insignificant prostate cancer

JAMA

Volumn 275, Issue 4, 1996, Pages 288-294

  Dugan, James A ^a   Bostwick, David G ^b   Myers, Robert P ^a   Qian, Junqi ^b   Bergstralh, Erik J ^b   Oesterling, Joseph E ^a,c  

^a DEPARTMENT OF UROLOGY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM;

EID: 0030040303     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.4.288     Document Type: Article

References (28)

1. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin. 1995;45:8-30.
2. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid H. Localized prostate cancer: relationship of tumor volume to clinical significance for the treatment of prostate cancer. Cancer 1993;71:993-938.
3. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
4. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330: 242-248.
5. US Bureau of the Census. Life tables. In: Vital Statistics of the United States. Washington, DC: US Bureau of the Census; 1990; section 6:1-19; section 7:22-23.
6. Stamey TA, McNeal JE, Freiha FS, Redwine EA, Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol. 1988;193: 1235-1240.
7. Lowe BA, Listrom MB. Incidental carcinoma of the prostate: analysis of the predictors of progression. J Urol. 1988;140:1340-1344.
8. Humphrey PA, Vollmer RT. Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum. Pathol. 1990;21:799-804.
9. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer. 1990;66:1225-1233.
10. McNeal JE. Origin and development of carcinoma of the prostate. Cancer. 1969;23:24-34.
11. Schmid H, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031-2040.
12. Csapo Z, Brand K, Walther R, Konstantinos F. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J Urol. 1988;140:1032-1038.
13. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 1993;72:2638-2643.
14. Bostwick DG, Graham SD, Napalkov P, et al. Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology. 1993;41: 403-411.
15. Kramer SA, Spahr J, Brendler CB, Glenn JF, Paulson DF. Experience with Gleason's histopathologic grading in prostatic cancer. J Urol. 1980;124: 223-225.
16. Gleason DF, Mellinger GT, and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58-64.
17. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol. 1992;23:258-266.
18. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate carcinoma. Prostate Suppl. 1992;4:129-138.
19. Klee GG, Dodge LA, Zincke Z, Oesterling JE. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J Urol. 1994;151:94-98.
20. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol. 1995;153:1543-1548.
21. Blackwell KL, Bostwick DG, Myers EP, Zincke H, Oesterling JE. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J Urol. 1994; 151:1565-1570.
22. McNeal JE, Kindrachuk RA, Freiha FS, Bostwick DG, Redwine EA, Stanley TA. Patterns of progression in prostate cancer. Lancet. 1986;1: 60-63.
23. Franks LM. Latent carcinoma of the prostate. J Pathol. 1954;68:603-616.
24. Villers AA, McNeal JE, Redwine EA, Freiha FS, Stamey TA. Pathogenesis and biological significance of seminal vesicle invasion in prostate adenocarcinoma. J Urol. 1990;143:1183-1187.
25. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 1995;45:75-80.
26. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology. 1994;44:862-867.
27. US Bureau of the Census. Life tables. In: Vital Statistics of the United States. Washington, DC: US Bureau of the Census; 1989; section 6:1-19; section 7:22-23.
28. Surveillance, Epidemiology, and End Results. Incidence and mortality data: 1973-1977. Bethesda, Md: National Cancer Institute; 1981. Monograph 57, publication NIH 81-2330.